192 results
Page 4 of 10
8-K
4n7ik
23 Apr 21
Entry into a Material Definitive Agreement
5:25pm
8-K
EX-10.1
52ykh
23 Apr 21
Entry into a Material Definitive Agreement
5:25pm
8-K
EX-4.1
mhapuqbcoi bnve
8 Apr 21
Entry into a Material Definitive Agreement
4:29pm
8-K
EX-10.1
gb0tin cu
5 Apr 21
Invitae Announces $1.15 Billion Investment Supporting Ongoing Growth Initiatives
4:13pm
8-K/A
EX-99.4
81p16hw
5 Apr 21
Financial Statements and Exhibits
4:11pm
8-K
EX-99.1
t6kqsoygik3q3 v124
17 Feb 21
Invitae Reports $279.6 Million in Annual Revenue Driven by 659,000 in Billable Volume in 2020
4:09pm
8-K
EX-1.1
88j02yoqmannzzyb
26 Jan 21
Invitae Announces Pricing of Public Offering of Common Stock
4:12pm
424B5
w7u9id1zp4lnu7fd
25 Jan 21
Prospectus supplement for primary offering
4:02pm
424B5
xsfdbz
20 Jan 21
Prospectus supplement for primary offering
4:24pm
8-K
EX-99.2
8mugv0gc5h5r2ju
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm
8-K/A
EX-99.1
y0klmj3yxvb3avnaxrzi
23 Nov 20
Consolidated Financial Statements
12:00am
8-K/A
EX-99.2
r2ypsp3sogyss
23 Nov 20
Consolidated Financial Statements
12:00am
8-K/A
EX-99.3
dqlywb fzrr
23 Nov 20
Consolidated Financial Statements
12:00am
8-K
EX-99.1
sbb 6wjr5ei1gf
5 Nov 20
Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020
4:24pm
8-K
EX-10.3
ctohcj0ne17hofm0
5 Oct 20
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
4:17pm
424B3
peuz3vran1iay
28 Aug 20
Prospectus supplement
4:31pm